These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 25998972)

  • 1. [Changing paradigm in the management of inflammatory bowel disease].
    Jang BI
    Korean J Gastroenterol; 2015 May; 65(5):268-72. PubMed ID: 25998972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.
    Florholmen J
    Scand J Gastroenterol; 2015 Jan; 50(1):43-52. PubMed ID: 25523555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New therapeutic goals in inflammatory bowel diseases].
    Vuitton L; Peyrin-Biroulet L
    Rev Prat; 2014 Nov; 64(9):1232-6. PubMed ID: 25638861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition and evaluation of mucosal healing in clinical practice.
    Mazzuoli S; Guglielmi FW; Antonelli E; Salemme M; Bassotti G; Villanacci V
    Dig Liver Dis; 2013 Dec; 45(12):969-77. PubMed ID: 23932331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep remission in inflammatory bowel disease: looking beyond symptoms.
    Zallot C; Peyrin-Biroulet L
    Curr Gastroenterol Rep; 2013 Mar; 15(3):315. PubMed ID: 23354742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
    Pineton de Chambrun G; Blanc P; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):915-27. PubMed ID: 27043489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease.
    Orlando A; Guglielmi FW; Cottone M; Orlando E; Romano C; Sinagra E
    Dig Liver Dis; 2013 Dec; 45(12):986-91. PubMed ID: 23993738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies in the management of inflammatory bowel disease.
    Rutgeerts P; Baert F
    Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I; Hasan F; Khan I
    Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC
    Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors.
    Bernardo S; Fernandes SR; Araújo-Correia L
    Rev Esp Enferm Dig; 2019 Aug; 111(8):593-597. PubMed ID: 31190548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapeutic approaches in inflammatory bowel disease.
    Sohrabpour AA; Malekzadeh R; Keshavarzian A
    Curr Pharm Des; 2010; 16(33):3668-83. PubMed ID: 21128898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.
    Breese EJ; Michie CA; Nicholls SW; Murch SH; Williams CB; Domizio P; Walker-Smith JA; MacDonald TT
    Gastroenterology; 1994 Jun; 106(6):1455-66. PubMed ID: 8194690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraintestinal Heterogeneity of Drug Target Expression in Inflammatory Bowel Disease.
    Swanson K; Younes M
    Ann Clin Lab Sci; 2024 Mar; 54(2):156-159. PubMed ID: 38802165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collagenous colitis development occurs after long standing mucosal healing in IBD with TNF-α inhibitors, and could be due to exaggerated healing response from excess TNF-α inhibition.
    Saad RE; Shobar R; Mutlu EA
    Med Hypotheses; 2019 Feb; 123():90-94. PubMed ID: 30696605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of treatment on morphological features of mucosal inflammation.
    Geboes K; Dalle I
    Gut; 2002 May; 50 Suppl 3(Suppl 3):III37-42. PubMed ID: 11953331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.